Earnings
PanGenomic Health Announces Financial Results for the 2025 Fiscal Year
PanGenomic Health Faces Dilution as Ayla BioScience Deal Reshapes Ownership Structure
Executive Summary
- Most Recent Release (May 1, 2026): The company filed its audited annual consolidated financial statements for the fiscal year ended December 31, 2025. No specific earnings figures or operational highlights are detailed in the release summary; it is an administrative filing notification available on SEDAR+.
- Prior Material Event (April 14, 2026): PanGenomic Health entered a Letter of Intent to acquire Ayla BioScience Inc. This transaction involves a change of control where existing PanGenomic shareholders will hold only 15-20% of the combined entity, while Ayla shareholders will hold 80-85%.
- Financing Context: In conjunction with the acquisition, PanGenomic intends to raise up to $2 million via private placement. This follows a similar $2 million non-brokered private placement completed in December 2025.
- Operational Updates (Late 2025): The company launched an Agenta DNA testing program integrated with its NaraCare.AI platform and signed an initial LOI for distribution of Ayla products in Canada, which has now escalated to a full acquisition proposal.
Material Impact
- Dilution Risk: The April 14 Letter of Intent represents a fundamental change where existing shareholders are diluted from majority ownership to minority status (15-20%). This is highly negative for current holders unless the Ayla assets significantly outweigh the dilution, which remains unproven.
- Capital Burn: The company has raised $4 million in less than six months ($2M in Dec 2025, $2M planned in April 2026). This indicates severe cash burn and a lack of organic revenue generation to sustain operations without constant equity financing.
- Trading Halt & Uncertainty: Trading was halted on April 14 pending the definitive agreement. The May 1 financial filing confirms the fiscal year-end but does not alleviate the uncertainty regarding the closing conditions (CSE approval, shareholder votes).
- Stock Price Reaction: The stock has declined from a high of $2.40 in September 2025 to $0.50 by April 30, 2026. The April 14 news coincided with a drop from $0.47 to $0.32 within days, reflecting market skepticism regarding the dilutive structure.
- Filing Impact: The May 1 filing is routine administrative work but confirms the fiscal year-end prior to the potential integration of Ayla. Without disclosed positive earnings in the snippet, it reinforces the narrative that capital was needed to survive the period leading up to this point.
NARA · Price
Company Overview
- Company: PanGenomic Health Inc. (CSE: NARA).
- Flagship Project: NaraCare.AI platform, a personalized wellness platform integrating DNA testing (Agenta) with AI insights for diet, fitness, and metabolism.
- Expansion: Recently expanded into functional foods and nutraceuticals via the proposed acquisition of Ayla BioScience, which utilizes ZeoDry™ dehydration technology and brands like ZeoMycel™.
- Development Stage: Commercialization phase (DNA kits sold in Canada), seeking expansion through M&A to scale product offerings.
More from PanGenomic Health Inc.
Apr 14, 2026 · 09:45